Intelligence Feed event · Macro · 2026-10-01

    Theriva Biologics Reports Phase 2b VIRAGE Survival Data in Nature Medicine

    Question

    Theriva Biologics Reports Phase 2b VIRAGE Survival Data in Nature Medicine

    Direct answer

    Theriva Biologics announced that Nature Medicine has published full clinical results from the Phase 2b VIRAGE study. The trial evaluated VCN-01, an engineered oncolytic adenovirus, administered alongside standard-of-care systemic chemotherapy. The published findings showed statistically meaningful gains in overall survival (OS), progression-free survival (PFS), and duration of response among patients treated for metastatic pancreatic adenocarcinoma, an indication with historically low survival rates.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Theriva Biologics Reports Phase 2b VIRAGE Survival Data in Nature Medicine”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/theriva-biologics-reports-phase-2b-virage-survival-data-in-nature-medicine-e606a5

    MACRO
    Theriva Biologics Reports Phase 2b VIRAGE Survival Data in Nature Medicine
    Theriva Biologics announced that Nature Medicine has published full clinical results from the Phase 2b VIRAGE study. The trial evaluated VCN-01, an engineered oncolytic adenovirus, administered alongside standard-of-care systemic chemotherapy. The published findings showed statistically meaningful gains in overall survival (OS), progression-free survival (PFS), and duration of response among patients treated for metastatic pancreatic adenocarcinoma, an indication with historically low survival rates.
    TOVX
    Impact
    72
    OCT 1
    SIG
    82%
    TOVX
    Theriva Biologics Reports Phase 2b VIRAGE Survival Data in Nature Medicine
    Theriva Biologics announced that Nature Medicine has published full clinical results from the Phase 2b VIRAGE study. The trial evaluated VCN-01, an engineered oncolytic adenovirus, administered alongside standard-of-care systemic chemotherapy. The published findings showed statistically meaningful gains in overall survival (OS), progression-free survival (PFS), and duration of response among patients treated for metastatic pancreatic adenocarcinoma, an indication with historically low survival rates.
    → Peer-reviewed Phase 2b survival data validates the VCN-01 mechanism of action, improving valuation support for TOVX's clinical oncology pipeline.
    Impact
    Theriva Biologics announced that Nature Medicine has published full clinical results from the Phase 2b VIRAGE study. The trial evaluated VCN-01, an engineered oncolytic adenovirus, administered alongside standard-of-care systemic chemotherapy. The published findings showed statistically meaningful gains in overall survival (OS), progression-free survival (PFS), and duration of response among patients treated for metastatic pancreatic adenocarcinoma, an indication with historically low survival rates.
    Affected
    TOVX
    Transmission
    Peer-reviewed Phase 2b survival data validates the VCN-01 mechanism of action, improving valuation support for TOVX's clinical oncology pipeline.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TOVXbiotech pipeline derisking via published Phase 2b survival dataUp1-4wPhase 2b VIRAGE trial publication in Nature Medicine showed improved OS and PFS in pancreatic cancer.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month